Drug Resistance in Cancer Therapy

Drug resistance remains a major obstacle in cancer treatment. It can be intrinsic or acquired and results from genetic mutations, tumor heterogeneity, or adaptive responses within cancer cells. Mechanisms include enhanced drug efflux, DNA repair activation, and altered drug targets. Resistance limits the efficacy of chemotherapy, targeted therapy, and immunotherapy, leading to disease relapse. Understanding these mechanisms helps in developing new strategies to overcome resistance, such as combination therapies, novel inhibitors, and personalized medicine approaches. Ongoing research focuses on biomarkers for early resistance detection and ways to re-sensitize tumors to previously ineffective treatments.

    Related Conference of Drug Resistance in Cancer Therapy

    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Drug Resistance in Cancer Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in